Enhancing Deinagkistrodon acutus antivenom potency through acutolysin A-targeted antibody supplementation.

ABSTRACT:

Background

Antivenom remains the standard and most effective treatment for snakebite envenomation, yet batch-to-batch variability in neutralization potency, even under standardized immunization protocols, continues to present a significant challenge in antivenom production worldwide. This issue is particularly evident in the manufacturing of Deinagkistrodon acutus antivenom in Taiwan, where some hyperimmunized equines fail to achieve the required potency despite identical conditions. Previous studies identified a lower antibody titer against acutolysin A-a key metalloproteinase toxin in D. acutus venom-as a potential contributor to reduced efficacy.

Methodology/principal findings

In this study, acutolysin A was purified from D. acutus venom using a two-step HPLC workflow, an

SUBMITTER: Liu CC 

PROVIDER: S-EPMC12714209 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature